{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-26-000217","form_type":"8-K","ticker":"ACTU","cik":"0001652935","company_name":"ACTUATE THERAPEUTICS, INC.","filed_at":"2026-01-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.771061+00:00","generated_at":"2026-05-16T10:53:19.648739+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Actuate Phase 2 pancreatic cancer trial meets OS endpoint; elraglusib+GnP reduces death risk 38%","bullets":["Median OS 10.1 mo (elraglusib/GnP) vs 7.2 mo (GnP alone); HR=0.62, p=0.02.","12-month survival doubled: 44.4% vs 22.3%; 24-month survival fivefold: 12.9% vs 2.6%.","Safety profile consistent; serious TEAE 56.1% vs 56.4%; death-related TEAE 12.3% vs 16.7%.","Biomarker data suggest potential predictive value for KRAS, ARID1A; increased CD8+ and NK cells in combination arm.","Seventeen patients remain alive in elraglusib arm (3 >24 mo); none on GnP alone as of Nov 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-26-000217","json":"https://secwatch.observer/filing/0001683168-26-000217.json","markdown":"https://secwatch.observer/filing/0001683168-26-000217.md","text":"https://secwatch.observer/filing/0001683168-26-000217.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1652935/000168316826000217/0001683168-26-000217-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1652935/000168316826000217/actuate_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T10:53:19.648739+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}